BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Regenesis Biomedical Appoints Vice President of Marketing


5/1/2008 9:54:30 AM

SCOTTSDALE, Ariz., May 1 /PRNewswire/ -- Regenesis Biomedical, Inc., a medical technology company that markets the Provant(R) Wound Therapy System, announced today that Scott Robey joined the company as Vice President of Marketing. Most recently Mr. Robey served as Senior Director of Marketing at Kinetic Concepts, Inc (KCI) for the V.A.C.(R) Therapy brand, during the time US product sales grew from approximately $70 million in 2000 to almost $1.0 billion in 2007.

(Photo: http://www.newscom.com/cgi-bin/prnh/20080422/LATU008)

"Scott is a proven leader with a record of successfully developing and executing significant growth strategies. His responsibilities include accelerating market penetration of the Provant Wound Therapy System, and expanding our platform technology into adjacent markets," said Virginia Rybski, Acting President of Regenesis. "Scott complements our senior management team, which has experience in early stage, rapidly developing companies, and management of mid-to-large medical technology organizations."

Mr. Robey is an 18 year marketing veteran. He held marketing positions at KCI, Medtronic, Sulzer Carbomedics, and Burron Medical (B. Braun Medical, Inc). His responsibilities have included product management, new product development and commercialization, branding, clinical education programs, and key opinion leader and society relationship development. Mr. Robey has an M.S. in Management from Purdue University, and a B.S. in Biomedical Engineering from Louisiana Tech University.

About the Provant Wound Therapy System

Provant delivers cell proliferation induction(R) (CPI(R)) therapy based on Regenesis' proprietary pulsed radio frequency energy (PRFE) core technology platform. PRFE uses an optimized radiofrequency signal to stimulate dormant cells, causing them to replicate and to produce natural growth factors and other gene expression products, which facilitate reduction of the pain and edema associated with post-operative wound healing in soft tissues. We believe Provant is effective, economical, and easy-to-use.

About Regenesis Biomedical

Regenesis Biomedical, Inc. is a privately held medical technology company focused on developing and marketing noninvasive regenerative medicine products. Regenesis developed, patented, and now markets the Provant Wound Therapy System. Our customers include health care facilities and providers that serve patients with wounds being treated by acute care hospitals, long- term acute care hospitals, skilled nursing facilities, rehabilitation centers, home health care agencies, and wound care clinics.



CONTACT: media, Scott Robey, VP Marketing, robey@regenesisbiomedical.com,
or clinicians, Rick Isenberg, MD, VP Clinical Affairs,
isenberg@regenesisbiomedical.com, or investors, Virginia Rybski, Acting
President, rybski@regenesisbiomedical.com, all of Regenesis Biomedical,
Inc., +1-480-970-4970

Web site: http://www.regenesisbiomedical.com/



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES